Multifaceted effect of chlorpromazine in cancer: implications for cancer treatment

Pareesa Kamgar-Dayhoff; Tinatin I. Brelidze

doi:10.18632/oncotarget.28010

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Reviews:

Multifaceted effect of chlorpromazine in cancer: implications for cancer treatment

Pareesa Kamgar-Dayhoff and Tinatin I. Brelidze _

PDF | Full Text | How to cite

Oncotarget. 2021; 12:1406-1426. https://doi.org/10.18632/oncotarget.28010

Metrics: PDF 1172 views | Full Text 4024 views | ?

Abstract

Pareesa Kamgar-Dayhoff1 and Tinatin I. Brelidze1

1 Department of Pharmacology and Physiology, Georgetown University Medical Center, Washington, D.C., USA

Correspondence to:

Tinatin I. Brelidze,

email:

[email protected]

Keywords: chlorpromazine; repurposing

Received: April 23, 2021 Accepted: June 14, 2021 Published: July 06, 2021

Copyright: © 2021 Kamgar-Dayhoff and Brelidze. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

ABSTRACT

Since its discovery in 1951, chlorpromazine (CPZ) has been one of the most widely used antipsychotic medications for treating schizophrenia and other psychiatric disorders. In addition to its antipsychotic effect, many studies in the last several decades have found that CPZ has a potent antitumorigenic effect. These studies have shown that CPZ affects a number of molecular oncogenic targets through multiple pathways, including the regulation of cell cycle, cancer growth and metastasis, chemo-resistance and stemness of cancer cells. Here we review studies on molecular mechanisms of CPZ’s action on key proteins involved in cancer, including p53, YAP, Ras protein, ion channels, and MAPKs. We discuss common and overlapping signaling pathways of CPZ’s action, its cancer-type specificity, antitumorigenic effects of CPZ reported in animal models and population studies on the rate of cancer in psychiatric patients. We also discuss the potential benefits and limitations of repurposing CPZ for cancer treatment.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 28010

Publication Alerts

Reviews:

Multifaceted effect of chlorpromazine in cancer: implications for cancer treatment

Abstract